The therapeutic community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s showing significant promise in clinical trials for treating obesity. Unlike some available weight loss approaches, retatrutide appears to deliver a more substantial decrease in body mass and enhance metabolic function, particula